Publication:
Tolerance biomarkers in liver transplantation: independent external validation of the predictive strength of SENP6 and FEM1C gene expression

Simple item page
dc.contributor.authorPerez-Sanz, Fernando
dc.contributor.authorRevilla-Nuin, Beatriz
dc.contributor.authorMartinez-Alarcon, Laura
dc.contributor.authorHerrero, José I.
dc.contributor.authorPons Miñano, José Antonio
dc.contributor.authorBaroja-Mazo, Alberto
dc.contributor.authorRamírez, Pablo (Ramírez Romero)
dc.contributor.departmentMedicina
dc.date.accessioned2025-01-26T10:44:17Z
dc.date.available2025-01-26T10:44:17Z
dc.date.issued2019-09
dc.description© 2019 Wolters Kluwer Health. This document is the Published version of a Published Work that appeared in final form in Transplantation. To access the final edited and published work see https://doi.org/10.1097/TP.0000000000002587
dc.description.abstractBackground. Numerous studies have emphasized the genetic and phenotypic profiles of tolerant transplant patients.Moreover, different groups have defined several biomarkers, trying to distinguish patients who are going to be tolerant from those who are going to reject. However, most of these biomarkers have not been validated by other groups or even established for clinical practice. Methods. We reanalyzed and stratified the predictive capacity of 20 previously described biomarkers for liver transplantation tolerance in a cohort of 17 liver transplant patients subjected to an independent, nonrandomized, prospective study of immunosuppression drug withdrawal. Results. Only 4 of the 20 studied biomarkers (expression of SENP6, FEM1C, miR31, and miR95) showed a strong predictive capacity in the present study. miR31 and FEM1C presented an area under the ROC curve of 96.7%, followed by SENP1 with 93.3%. Finally, miR95 had an area under the ROC curve value <86.7%. Conclusions. Even though this independent analysis seems to confirm the predictive strength of SENP6 and FEM1C in liver transplantation tolerance, there are also risks in establishing biomarkers for clinical phenotypes without an understanding of how they are biologically relevant. Future collaborations between groups should be promoted so that the most promising biomarkers can be validated and implemented in daily clinical practice.es
dc.formatapplication/pdfes
dc.format.extent6es
dc.identifier.citationTransplantation 103(9):p 1887-1892
dc.identifier.doihttps://doi.org/10.1097/TP.0000000000002587
dc.identifier.issnPrint: 0041-1337
dc.identifier.issnElectronic: 1534-6080
dc.identifier.urihttp://hdl.handle.net/10201/149313
dc.languageenges
dc.publisherLippincott, Williams & Wilkinses
dc.relationThis work was supported by a grant from Instituto de Salud Carlos III (PI12/02042 and PI17/00489) for J.A.P. and Fundación Mutua Madrileña (FMM13) for A.B.-M. as Principal Investigators. Clinical trial notation: www.isrctn.com; number ISRCTN15775356.es
dc.relation.publisherversionhttps://journals.lww.com/transplantjournal/fulltext/2019/09000/tolerance_biomarkers_in_liver_transplantation_.25.aspx
dc.rights.accessRightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectLiver transplantationes
dc.subjectBiomarkers
dc.subjectGene expression
dc.titleTolerance biomarkers in liver transplantation: independent external validation of the predictive strength of SENP6 and FEM1C gene expressiones
dc.typeinfo:eu-repo/semantics/articlees
dspace.entity.typePublicationes
relation.isAuthorOfPublicatione64e013c-bc8c-4eae-ad1e-9bd89655a6d0
relation.isAuthorOfPublication.latestForDiscoverye64e013c-bc8c-4eae-ad1e-9bd89655a6d0
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
tolerance_biomarkers_in_liver_transplantation_.25-2.pdf
Size:
326.24 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.26 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Artículos